Ophthalmology 2021 May 3. Epub 2021 May 3.
Department of Ophthalmology, University of Bonn, Bonn, Germany;; Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT, USA.
Purpose: This trial was conducted to investigate the clinical equivalence of the proposed biosimilar FYB201 and reference ranibizumab in patients with treatment-naive, subfoveal choroidal neovascularization caused by neovascular age-related macular degeneration (nAMD).
Design: This was a prospective, multicenter, evaluation-masked, parallel-group, 48-week, phase III randomized study.
Participants: A total of 477 patients were randomly assigned to receive FYB201 (n = 238) or reference ranibizumab (n = 239). Read More